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The mechanisms through which tumor antigen-specific T cells are elicited in natural or chemotherapy-
induced immunosurveillance have been elusive. In this issue of Cancer Cell, two papers by Broz and col-
leagues and Ruffell and colleagues delineate an important role for a specific dendritic cell subset character-
ized byCD103 expression, dependence on transcription factorsBatf3 and Irf8, and interleukin-12 production.Cancers progress in an unrestrained
fashion when immunosurveillance fails or
when tumor cells either actively suppress
the anticancer immune response or suc-
cessfully hide from recognition by lym-
phocytes. Specific recognition of tumor
antigens by CD8+ cytotoxic T lympho-
cytes producing a particular interferon-g
(IFN-g)-centered cytokine pattern (Tc1
cells) is one of the cardinal features of
natural or therapy-induced immunosur-
veillance, and the abundance of such
Tc1 cell in the tumor at diagnosis has a
positive prognostic impact on major hu-
man malignancies (Fridman et al., 2012).
Accordingly, the effects of conventional
anticancer therapies largely correlate
with preexisting Tc1 cell infiltration (Stoll
et al., 2014; Zitvogel et al., 2013). Deple-
tion of CD8+ T cells or neutralization or
ablation of IFN-g or its receptor abolishes
the beneficial effects of chemotherapy in
mouse models (Kroemer et al., 2013).
Accumulating evidence indicates that
the local function of T lymphocytes is gov-
erned by a panel of distinct myeloid cell
subpopulations that modulate the recruit-
ment, antigen-specific activation, and
function of T cells. Broz et al. (2014; in
this issue of Cancer Cell) performed
extensive immunophenotypic, functional,
and gene expression profiling of myeloid
cells contained in mouse tumors to distin-
guish at least four subtypes: TAM1 (tu-
mor-associated macrophage type 1 cells,
CD11cloCD11bhiMHCIIhi), TAM2 (tumor-
associated macrophage type 2 cells,CD11chiCD11bloMHCIIlo), CD11b+ DC1
(dendritic cell type 1 cells), and CD103+
DC2 (dendritic cell type 2 cells). CD103+
DC2 expressed typical DC markers (and
hence were CD135(Flt3)+CD117(cKit)+
CD26+) and exhibited distinct tran-
scriptional signatures consistent with
enhanced cross-presentation, increased
costimulation, and heightened expression
of chemokines that may enhance T cell
interaction (such as CCL5) (Figure 1).
Moreover, CD103+ DC2 were able to
maintain a basic endocytic compartment
and, consistently, were particularly effi-
cient in stimulating naive tumor antigen-
specific T cells in vitro, suggesting that
CD103+ DC2 might play an active role in
stimulating anticancer immune responses
(Broz et al., 2014).
Broz et al. (2014) found that CD11c-
Cre;Irf4fl/fl mice lacked intratumoral
CD11b+ DC1, while Batf3/ and Irf8/
mice lacked CD103+ DC2. Moreover,
diphtheria toxin (DT) injection into mice
expressing a DT receptor (DTR) transgene
controlled by the Zbtb46 (zDC) promoter
(zDC-DTR mice) only depleted intratu-
moral CD103+ DC2, not CD11b+ DC1.
Cancer cells engineered to express
CSF2 (also known asGM-CSF) selectively
expanded CD11b+ DC1 within the tumor
bed, while malignant cells expressing
Flt3L preferentially expanded CD103+
DC2. These data support the idea that
the DC subtypes are ontogenetically and
functionally distinct (Broz et al., 2014).
Tumor growth was accelerated in Irf8/Cancer Cell 26, Nmice but not in CD11c-Cre;Irf4fl/fl mice,
in line with the possibility that only
CD103+ DC2 (but not CD11b+ DC1)
participate in immunosurveillance as pre-
viously suggested (Hildner et al., 2008).
Moreover, adoptive transfer of tumor
antigen-specific T cells largely failed to
reduce tumor growth in DT-treated zDC-
DTR mice (depleted for CD103+ DC2)
that simultaneously received FTY-720 to
block T cell egress from lymph nodes
(Broz et al., 2014). Altogether, these re-
sults suggest a role for intratumoral
CD103+ DC2 in priming tumor antigen-
specific T cells.
Of note, CD103+ DC2 expressed higher
levels of IL12b (coding for the IL-12p40
subunit) than any other myeloid subset,
yet failed to express immunosuppressive
cytokine IL-10, which was expressed by
the other subsets (Broz et al., 2014), pri-
marily TAM2 cells (Ruffell et al., 2014;
in this issue of Cancer Cell). Moreover,
this functional dichotomy, which was
measured in untreated chemotherapy-
naive tumors (Broz et al., 2014), had rele-
vance for the chemotherapeutic response
to paclitaxel. In a model of oncogene-
induced breast cancer, Ruffell et al.
(2014) found that CSF1 neutralization
with amonoclonal antibody (mAb) caused
selective depletion of TAM1 and TAM2
(but not of CD11b+ DC1 or CD103+ DC2)
and improved paclitaxel-induced tumor
growth reduction similar to mAb-medi-
ated IL-10 neutralization. Because the
combined injection of aCSF1 and aIL-10ovember 10, 2014 ª2014 Elsevier Inc. 591
Figure 1. Functionally Important Myeloid Cells in the Tumor Bed
Tumor-associated macrophages type 2 (TAM2), which can be depleted by neutralizing CSF-1 antibodies, produce interleukin-10 (IL-10), which reduces the
number and inhibits the function of CD103+ type 2 dendritic cells (DC2). DC2, which can be stimulated by paclitaxel-based chemotherapy, present tumor antigens
to CD8+ T cells and produce IL-12 to facilitate the polarization of primed CD8+ T cells to a cytotoxic T cell 1 (Tc1) pattern of cytokine production. These Tc1 cells
are the final effectors of anticancer surveillance.
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Previewsdid not confer any further reduction in
tumor volume, the therapeutic effects of
aCSF1 may be explained entirely by the
removal of the IL-10 source. The anti-
cancer effects of aCSF1 and aIL-10
were similar in that they both increased
the frequency of CD11b+ DC1 and
CD103+ DC2 as well as the expression
of IL12a (coding for the IL-12p35 subunit)
in these populations. Both neutralizing
mAbs also increased the expression of
IL12b (coding for the IL-12p40 subunit)
in CD103+ DC2 only, conferring expres-
sion of the functional IL-12 p70 hetero-
dimer. Because neutralization of either
IL-12p40 or IL-12p70 fully abolished the
tumor growth reduction observed with
paclitaxel combined with aCSF1 or aIL-
10, it appears that IL-12 must act as a
positive regulator of therapy-induced im-
munosurveillance downstream of TAM1/592 Cancer Cell 26, November 10, 2014 ª20TAM2 depletion and IL-10 neutralization
(Ruffell et al., 2014).
Although all the aforementioned results
were obtained in mouse models, there is
evidence that they may also have some
relevance to human cancer. High mRNA
levels of IL12A (but not IL12B) as well as
IRF8 predicted pathological complete re-
sponses after paclitaxel-based chemo-
therapy in breast cancer patients (Ruffell
et al., 2014). Similarly, several mRNAs
associated with CD103+ DC2 (such as
BATF3, CCR7, FLT3, and KIT) had a
positive prognostic impact on a large
collection of human cancers. This also
applies to a ‘‘CD103+/ ratio’’ obtained
by dividing the signature of genes associ-
ated with CD103+ DC2 by those associ-
ated with all other myeloid subsets.
A high ‘‘CD103+/ ratio’’ predicted
improved overall survival in breast cancer,14 Elsevier Inc.head and neck squamous cancer, and
lung adenocarcinoma (Broz et al., 2014).
The aforementioned data support the
notion that CD103+ DC2 producing IL-12
play a cardinal role in natural and pacli-
taxel-induced anticancer immunosurveil-
lance in mouse models of breast cancer
as well as human cancer. However, these
results contrast with the observation
that doxorubicin-induced reduction of
EL4 thymoma growth was intact in IL-
12Rb/ mice (Ghiringhelli et al., 2009)
and that F244 sarcoma cells responded
to doxorubicin in Batf3/ hosts (Ma
et al., 2013). Unfortunately, no systematic
study has addressed whether distinct DC
subsets are involved in anticancer im-
mune responses induced by different
chemotherapeutics in the context of dif-
ferent tumor types or anatomical localiza-
tions. Moreover, there are discrepancies
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DC subsets within the tumor bed. Broz
et al. (2014) found that both CD11b+
DC1 and CD103+ DC2 were preferentially
located in collagen-rich zones distal to the
tumor nodules where TAM1 and TAM2
cells were found. In contrast, Ruffell
et al. (2014) report that CD103+ cells
were dispersed throughout the tumor
stroma in the proximity of macrophages.
Although Ruffell et al. (2014) found
no change in the localization of CD103+
cells after treatment with paclitaxel and
aCSF-1, Ma et al. (2013) found that
CD11b+ cells exhibited a selective
tropism for dying tumor cells after doxoru-
bicin treatment.
Irrespective of these discrepancies,
however, the accumulating evidence sug-
gests that some DC subpopulations can
cross-present tumor antigens within the
cancer without needing to migrate to
lymph nodes. Thus, lymphadenectomy
fails to affect the anticancer immune
response elicited by anthracycline-basedchemotherapy (Ma et al., 2013, 2014).
Moreover, direct purification of intratu-
moral DC subsets yields functional tumor
antigen-presenting cells that are able to
prime naive T cells in vitro (Broz et al.,
2014) and elicit anticancer immune
response upon adoptive transfer in vivo
(Ma et al., 2013). These results reinforce
the idea that the tumormay be considered
as a full-blown lymphoid organ, in which
all steps of cellular immune responses
starting with appropriate presentation of
tumor antigens by dendritic cells occur
in situ.REFERENCES
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In this issue of Cancer Cell, Garsed and colleagues combine chromosome flow sorting and deep sequencing
to characterize the structure of oncogene-containing neochromosomes in liposarcoma and provide evidence
that they are generated by a combination of multiple dynamic and destructive processes.Loss of genomic integrity in cancer has
many differentmanifestations. In this issue
ofCancer Cell, Garsed et al. (2014) investi-
gate one of the most convoluted products
of this genomic instability—the neochro-
mosome, characteristic of well-differenti-
ated/dedifferentiated liposarcoma (WD/
DDLPS). The term ‘‘neochromosome’’ de-
scribes a marker chromosome whose
origin cannot be determined by conven-
tional chromosome banding techniques,
which emphasizes their extreme diver-
gence in size and structure from anynormal chromosome. By combining
chromosome flow sorting and deep
sequencing, Garsed et al. (2014) charac-
terize the structure of these remarkably
large and highly rearranged structures
and propose a model for their genesis
and growth. Undergoing multiple rounds
of such catastrophic events as chromo-
thripsis, breakage-fusion-bridge cycles,
and centromere erosion, their survival is a
testament to the power of selection and
theability of tumors to leveragedestructive
processes for their own benefit.The heterogeneous collection of malig-
nant tumors of adipose tissue known as
liposarcomas constitutes roughly 20% of
all sarcomas (Dei Tos, 2014). The most
common subtype of liposarcoma, ac-
counting for nearly half of all cases, is the
WD/DDLPS, also referred to as atypical
lipomatous tumor in some circumstances.
Although the higher grade DDLPS is
metastatic in roughly 20% of cases, the
primary difficulty of this malignancy is
associated with local aggressiveness
and recurrence. Early cytogenetic studiesovember 10, 2014 ª2014 Elsevier Inc. 593
